论文部分内容阅读
目的探讨海藻酸钠微球(KMG)经肝动脉栓塞治疗肝细胞癌(HCC)的近期临床疗效。方法回顾性分析应用KMG经肝动脉栓塞治疗2009年7月至2012年11月间在我院肝细胞癌治疗的54例HCC患者的临床资料,分析其相关不良反应、并发症及肿瘤的近期疗效。结果所有患者均成功行栓塞治疗,术后不良反应包括:肝区疼痛66.67%(36/54),发热55.56%(30/54),恶心、呕吐27.78%(15/54),无严重并发症发生;22例HCC患者合并肝动脉门静脉分流(APS)或肝动脉肝静脉分流(AVS);术后2个月CT或MR复查,并测量肿瘤大小,按改良的实体瘤疗效评价(RECIST)标准评价:部分缓解29.63%(16/54),稳定57.41%(31/54),进展12.96%(7/54)。结论 KMG栓塞治疗HCC是安全的,近期疗效显著。
Objective To investigate the short-term clinical efficacy of sodium alginate microspheres (KMG) in the treatment of hepatocellular carcinoma (HCC) by hepatic artery embolization. Methods The clinical data of 54 patients with hepatocellular carcinoma treated by KMG transcatheter hepatic arterial embolization from July 2009 to November 2012 in our hospital were retrospectively analyzed. The related adverse reactions, complications and the short-term effect of the tumor were analyzed . Results All patients underwent successful embolization. The postoperative adverse reactions included 66.67% (36/54) in the liver area, 55.56% (30/54) in the liver area, 27.78% (15/54) in the nausea and vomiting, and no serious complications (APS) or hepatic artery hepatic vein shunt (AVS) in 22 patients with HCC. CT or MR were performed at 2 months after operation and the tumor size was measured. According to the RECIST standard Evaluation: partial response was 29.63% (16/54), stable 57.41% (31/54), progress 12.96% (7/54). Conclusions KMG embolization is safe for HCC and has a short-term curative effect.